640 related articles for article (PubMed ID: 33371069)
21. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
[TBL] [Abstract][Full Text] [Related]
22. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Glück S; Castrellon A
Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
Dai S; Zhang Y; Tan X; Luo F; Yan X
Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
[TBL] [Abstract][Full Text] [Related]
24. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study.
Gao M; Fu C; Li S; Chen F; Yang Y; Wang C; Qin J; Liu S; Zhang R; Wang C; Zong J; Meng L; Meng X
Cancer Med; 2022 Feb; 11(3):735-742. PubMed ID: 34962098
[TBL] [Abstract][Full Text] [Related]
26. The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China.
Wang X; Wang L; Yu Q; Liu Z; Li C; Wang F; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211037812. PubMed ID: 34342244
[TBL] [Abstract][Full Text] [Related]
27. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
[TBL] [Abstract][Full Text] [Related]
28. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
Xie XF; Zhang QY; Huang JY; Chen LP; Lan XF; Bai X; Song L; Xiong SL; Guo SJ; Du CW
Breast Cancer Res Treat; 2023 Jan; 197(1):93-101. PubMed ID: 36309908
[TBL] [Abstract][Full Text] [Related]
29. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract][Full Text] [Related]
30. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
[TBL] [Abstract][Full Text] [Related]
31. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
33. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
[TBL] [Abstract][Full Text] [Related]
34. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
35. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
37. Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.
Wang N; Li L; Xiong Y; Chi J; Liu X; Zhong C; Wang F; Gu Y
Front Oncol; 2021; 11():729212. PubMed ID: 34976791
[TBL] [Abstract][Full Text] [Related]
38. Pyrotinib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(16):1751-1755. PubMed ID: 30341682
[TBL] [Abstract][Full Text] [Related]
39. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Yan M; Ouyang Q; Sun T; Niu L; Yang J; Li L; Song Y; Hao C; Chen Z; Orlandi A; Ishii N; Takabe K; Franceschini G; Ricci F; Verschraegen C; Liu Z; Zhang M; Lv H; Liu L; Yang X; Xiao H; Gao Z; Li X; Dong F; Chen X; Qiao J; Zhang G
Lancet Oncol; 2022 Mar; 23(3):353-361. PubMed ID: 35085506
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
